Gilead Sciences has been granted marketing authorization by the European Commission for its Idelalisib 150mg tablets (to be marketed as Zydelig) to treat the two incurable blood cancers Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL). This formidable first-in-class oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, plays a key role in the activation, proliferation and[…]
Idelalisib EU Approval Granted For Treating CLL and FL Patients
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014 Tags: chronic lymphocytic leukemiaCLLIdelalisibRituximab Sep 24, 2014
Idelalisib FDA Approved to Combat Three Blood Cancers
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014 Tags: chronic lymphocytic leukemiaIdelalisibRituximab Jul 28, 2014
Gilead has announced the July 23, 2014 Idelalisib FDA approved news. The Idelalisib (or the brand name Zydelig) approval was long awaited, to combat three forms of blood cancer. The FDA extended a nod to this powerful drug, which is estimated to earn roughly 1.2 billion dollars by the year 2020. Approved to treat three type[…]
Idelalisib Is a Leader in Oncology Treatment
Chemotherapeutic / Anti-Neoplastic, NDA Tags: chronic lymphocytic leukemiaCLLIdelalisibRituximab Jun 18, 2014
Idelalisib has captured the attention of pharmaceutical research and development teams with the latest data touting its targeted treatment for both unresectable non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The FDA accepted Gilead Sciences’ new drug application early in 2014 for the treatment of refractory indolent NHL, and the target review date for the[…]
Breaking News: No Heightened Risk of Shingles for Patients Taking Newer Rheumatoid Arthritis Medications
Anti-Inflammatory, Anti-Psoriatic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 331731-18-1AdalimumabEtanerceptHumiraRheumatoid ArthritisRituximab Mar 18, 2013
On March 6, 2013 encouraging results from a study involving rheumatoid arthritis medications were published. This study, available in the March 6 issue of the Journal of the American Medical Association, reassured patients who are taking the newest medications. Results concluded from this particular study revealed that these drugs do not appear to raise the[…]
Pixantrone Maleate as a New Treatment for Patients with Non-Hodgkin's Lymphoma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AnthracyclinesDrug AdministrationRituximab Feb 13, 2012
Pixantrone maleate, CAS Number 146675-97-8, is an anthracenedione anthracycline derivative, developed by Cell Therapeutics Incorporated. Pixantrone maleate is used for treatment of patients with non-Hodgkin’s lymphoma. LGM Pharma is a provider of pixantrone maleate for research and development purposes. As a promising treatment for aggressive non-Hodgkin’s lymphoma, pixantrone maleate is well tolerated when substituted for[…]
Monoclonal Antibodies (mAbs) – Growth, Supply, and Uses for Cancer Treatment
Antithrombotic, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 180288-69-1331731-18-1AdalimumabAlemtuzumabBevacizumabchemotherapyEGFRRituximabTrastuzumab Feb 11, 2011
What Are Monoclonal Antibodies? A monoclonal antibody is a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells. Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system’s response to germs, vaccines and other invaders. Growing Interest for Monoclonal Antibody Therapies Monoclonal antibodies were initially[…]
